Post-Transplant Lymphoproliferative Disorder in Children Prognosis, and Treatment Options

tion in children is a serious complication that has been responsible for high mortality rates over recent years. PTLDs are part of a clinically and histologically heterogeneous group of B-lymphocyte proliferations mostly induced by Epstein-Barr virus (EBV) in a context of immunosuppression. Major risk factors for PTLDs in solid organ transplantation are the EBV serostatus mismatch and the intensity, duration, and type of immunosuppression. T-cell depletion and the HLA-mismatched donor and recipient are the main risk factors following hematopoietic stem cell transplantation. For a long time, the only safe and effective therapeutic approach to PTLD was reduction of immunosuppression, with a risk of graft rejection. Based on a better knowledge of the pathophysiology and risk factors for PTLD, preventive and pre-emptive strategies have been recently proposed to control PTLD. New treatment modalities, such as anti-B-cell antibodies, cytokine inhibitor therapy, or anti-EBV cytotoxic T lymphocytes are promising and may improve the outcome of PTLD. These therapeutic

[1]  H. Heslop,et al.  Post-transplant lymphoproliferative disorders. , 2005, Annual review of medicine.

[2]  I. Penn.  The role of immunosuppression in lymphoma formation , 2004, Springer Seminars in Immunopathology.

[3]  G. Remuzzi,et al.  Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome , 2002, Transplantation.

[4]  A. Rickinson.  Epstein-Barr virus. , 2001, Virus research.

[5]  H. Einsele,et al.  MOLECULAR PATHOGENESIS OF EPSTEIN-BARR VIRUS ASSOCIATED POSTTRANSPLANT LYMPHOMAS: NEW INSIGHTS THROUGH LATENT MEMBRANE PROTEIN 1 FINGERPRINTING1 , 2001, Transplantation.

[6]  B. van der Holt,et al.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. , 2001, Blood.

[7]  A. Fischer,et al.  Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. , 1998, Blood.

[8]  D. Faller,et al.  Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. , 1998, Blood cells, molecules & diseases.

[9]  M. Picot,et al.  PREVALENCE OF MONOCLONAL IMMUNOGLOBULINS AFTER LIVER TRANSPLANTATION , 1998 .

[10]  A. Cheung,et al.  Post-transplantation lymphoproliferative disorder of donor origin in a sex-mismatched renal allograft as proven by chromosome in situ hybridization. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[11]  I. Penn,et al.  Central Nervous System Lymphomas In Organ Allograft Recipients , 1995, Transplantation.

[12]  S. Riddler,et al.  Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. , 1994, Blood.

[13]  R. Shapiro,et al.  Epstein-Barr virus--determined clonality in posttransplant lymphoproliferative disease. , 1990, Transplantation.

[14]  B. Griffith,et al.  Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. , 1985, The Journal of infectious diseases.